A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2029

Conditions

Breast Cancer

Interventions

DRUG

Cyclophosphamide

Given by mouth

DRUG

Axatilimab (SNDX-6352)

Given by IV

DRUG

Retifanlimab

Given by IV

Trial Locations (1)

The University of Texas M. D. Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER